Posts by: Ana Pena, PhD

Ana Pena, PhD

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

October 16, 2019

Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows

News

Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or ... Read more

October 4, 2019October 8, 2019

Lenvima-Keytruda Combo Maintains Positive Results in Advanced Endometrial Cancer

News

Combination therapy with Lenvima (lenvatinib) and Keytruda (pembrolizumab) continues to show promising antitumor results in patients with advanced endometrial cancer, the most common cancer of the uterus, according to the ... Read more

September 4, 2019

Trial of Targeted Radiation Therapy, CLR 131, in Children with Advanced Cancers Moving to Higher Dose

News

Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid ... Read more

July 17, 2019

Transgene Completes Enrollment for Phase 2 Trial of Triple Combo NSCLC Therapy

News

Transgene has completed patient enrollment for its Phase 2 trial evaluating the cancer vaccine TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small ... Read more

May 29, 2019May 29, 2019

Cue Biopharma to Launch CUE-101 Immunotherapy Trial for Head and Neck Cancer Caused by HPV

News

The U.S. Food and Drug Administration (FDA) has accepted Cue Biopharma‘s investigational new drug (IND) application for its immunotherapy candidate CUE-101, clearing the way for the first-in-human Phase 1 trial ... Read more

May 22, 2019

Japanese Researchers Use Hyperion Imaging Tool to Advance Treatment Discovery for Colorectal Cancer

News

The National Cancer Center (NCC) in Japan is advancing its research into novel immunotherapies for colorectal cancer by using the Hyperion Imaging System, a powerful tool that enables simultaneous visualization ... Read more

May 14, 2019

$4.6M CIRM Grant to Fund Phase 1 Trial of New Immunotherapy for Advanced Sarcoma, Difficult-to-Treat Cancers

News

The California Institute for Regenerative Medicine (CIRM) has awarded a $4.6 million grant to researchers at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research for ... Read more

April 12, 2019

Early Phase 3 Trial Results of Tedopi for Advanced NSCLC Are Positive

News

Early results from the ATALANTE-1 Phase 3 trial indicate that Tedopi benefits people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior checkpoint inhibitor therapy, OSE ... Read more

April 2, 2019

INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says

News

Therapy candidate INB03, meant to inactivate a kind immunosuppressive cell called myeloid-derived suppressor cells (MDSCs) while boosting anti-tumor immune cells, may help overcome resistance to immunotherapies, including immune checkpoint inhibitors, INmune Bio’s ... Read more

March 29, 2019

Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows

News

Combining anti-PD-L1 immunotherapies with agents that inhibit the DNA damage response (DDR) significantly enhances anti-tumor immunity and leads to rapid tumor disappearance in mouse models of small cell lung cancer (SCLC), a ... Read more